Nanologica AB (SE:NICA)
:NICA
Want to see SE:NICA full AI Analyst Report?
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.33 - kr2.25
Previous CloseN/A
Volume105.00
Average Volume (3M)111.94K
Market Cap
kr189.37M
Enterprise Valuekr139.41M
Total Cash (Recent Filing)kr39.25M
Total Debt (Recent Filing)kr119.07M
Price to Earnings (P/E)2.0
Beta1.37
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding328,769,840
10 Day Avg. Volume89,035
30 Day Avg. Volume111,941
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr141.40M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained TTM revenue growth of ~50% signals real commercial traction in pharmaceutical markets. Over 2–6 months this supports scale economies, validates product-market fit for silica media, and creates a firmer base to expand commercial footprint and fund targeted R&D or capacity investments.
Specialized Silica Technology PlatformA focused silica-based chromatography platform tailored to pharmaceutical purification is a durable competitive asset. Technical specialization aligns with regulated, high-barrier applications, enabling deeper customer integration and long-term relevance as drug manufacturing quality and purification demands persist.
Positive Equity And Larger Asset BaseReporting positive equity and materially larger assets provides a financial buffer to support growth and operations. Improved balance-sheet scale enhances capacity to invest in production, absorb near-term losses, and negotiate partnerships or financing on better terms versus a de-capitalized peer.
Bears Say
Persistent Operating LossesContinued negative gross and operating profits show core operations are not yet self-sustaining. Over months this undermines durability of growth since margin expansion is required to convert revenue gains into free cash, and reported net income includes non-operating items that weaken earnings quality.
Negative Cash GenerationSustained negative operating and free cash flow indicate ongoing cash burn and reliance on external financing. This reduces strategic flexibility, raises dilution or refinancing risk, and constrains the company's ability to internally fund capex, scale production, or sustain longer sales cycles common in pharma.
Rising LeverageHigher debt-to-equity while core operations lose money raises solvency and interest-service risks. Increased leverage limits flexibility for cyclical downturns or R&D investment, elevates refinancing pressure over the medium term, and can amplify downside if margin recovery stalls.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.33 and its highest was kr2.25 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr189.37M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Aug 27, 2026 which is in 75 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on May 20, 2026. The company reported kr0.719 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.719.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of kr0.719 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 32.383%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Founded in Södertälje, Sweden, in 2004, Nanologica AB (publ) is a nanotechnology company dedicated to creating nanoporous silica. This specialized material finds critical applications within the life science industry, particularly in drug development and chromatography separation. The firm's comprehensive product line features the NLAB Silica platform for advanced drug delivery, the NLAB Spiro inhalation platform targeting pulmonary administration, SVEA (U)HPLC analytical columns, and systems for preparative chromatography.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―